GlassScriptPhysician profile
Jacqueline Gutmann
NPI 1063579431
$6,665.53
in general payments reported to CMS, 2019-2025
12 companies · $151 in 2025
The $151 reported for 2025 was more than what a typical Reproductive Endocrinology provider received nationally (typical 2025 total: $140).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,485 · 2020: $107 · 2021: $53.65 · 2022: $182 · 2023: $502 · 2024: $185 · 2025: $151.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $838.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $838.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $4,850.12 | 2019 | |
| Emd Serono, INC. | $705.02 | 2019-2024 | |
| Organon LLC | $591.38 | 2021-2025 | Pregnyl, Follistim Aq, Ganirelix Acetate |
| Merck Sharp & Dohme LLC | $170.77 | 2019-2020 | |
| Abbvie INC. | $138.14 | 2019-2021 | |
| Vertical Pharmaceuticals, LLC | $82.64 | 2019-2020 | |
| Galen US INC | $30.52 | 2019 | |
| Exeltis, USA INC. | $29.91 | 2019 | |
| Covidien LP | $20.15 | 2019 | |
| Evofem Biosciences, INC. | $17.51 | 2022 | |
| Cook Medical LLC | $15.41 | 2019 | |
| Virtus Pharmaceuticals LLC | $13.96 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jacqueline Gutmann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.